Allergic contact dermatitis to topical medicaments: Revisited

Supitchaya Thaiwat,1 Taksaorn Ubol1

Abstract

Background: Allergic reaction to topical drugs varies depending on use and availability of topical drugs and self-medication.

Objectives: We aimed to determine the incidence of contact dermatitis to topical medicaments among patients referred for patch testing.

Methods: All patients with suspected allergic contact dermatitis were patch tested with standard and medicament series. The characterization was performed according to the MOAHLFA index.

Results: 59/215 (27.4%) patients had positive reactions to at least 1 medicament but only 13/59 (22.0%) had a relevant history. The 3 most common positive medicaments were framycetin 23/215 (10.7%), miconazole 22/215 (10.2%), and econazole 17/215 (7.9%). Among those positive to medicament, face was the most common location 22/59 (37.3%). 39/215 (18.1%) had more than 2 co-positive standard allergens and showed significant higher rate of topical medicament sensitization. The contributing factors of medicament allergy were the history of suspected allergens in personal care products (OR = 2.09, \(P = 0.038\)), topical drugs (OR = 2.93, \(P = 0.002\)), topical treatment (OR = 2.47, \(P = 0.011\)), and history of drug allergy (OR = 1.78, \(P = 0.023\)).

Conclusion: The study showed a high rate of medicament sensitization especially antibiotic and antifungal drugs. The incidence of positive medicament patch test result was associated with facial dermatitis. Polysensitization and history of previous exposure, either as treatment or overusing of drugs, significantly associated with medicament positive patients. This study supports the inclusion of medicaments within the standard series of patch test.

Key words: allergic contact dermatitis, topical medicaments, patch test, contact sensitization, contributing factors

Introduction

Allergic contact dermatitis is an inflammatory reaction due to exposure with exogenous allergen and responds by delayed type hypersensitivity. The incidence of allergic contact dermatis to topical medicament varies in each country. The contributing factors can be age, race, area of involvement, underlying diseases, accessibility to drugs and prescriptions together with self-medication habits of the population.1-4 The rate of topical medicament sensitization in South East Asian contact dermatitis patients was last reported in 1989 at overall 22.5%.1 Medication including topical drugs is loosely regulated and can easily be purchased over the counter in Thailand. Most patients still prefer to buy drugs directly from a pharmacy over obtaining prescription from a doctor. Owing to the self-medication habit of the population, a variety of “one cream treats all” formulations are available containing corticosteroid, antibiotics and/or antifungal agents.
The exposure to such medicaments may induce contact sensitization. We aimed to determine the recent incidence of contact dermatitis to topical medicaments among patients referred for patch testing.

Materials and Methods

We conducted a prospective study in a tertiary referral medical center over a period of 1 year from 1st June 2014 to 31st May 2015. The study was approved by the Institutional Review Board of Royal Thai Army Medical Department (IRBRTA 322/2557). Patients who were suspected to have allergic contact dermatitis to allergens such as personal care products and topical drugs aged at least 18 years old were recruited for patch testing with standard series and topical medicament series. The exclusion criteria comprised of pregnancy, underlying diseases of immune abnormality e.g. human immunodeficiency virus positive or lupus erythematosus, and history of severe allergic reaction i.e. anaphylaxis. Patch test results were read at 72 hours and 96 hours with an extension up to 7 days in some patients in case of delayed patch test reaction, e.g. patients who had negative result to aminoglycoside. Readings were in accordance with standard ICDRG readings were scored as -, ?+, +, ++, or ++++. Only + reaction or more were regarded as true positive. The patients were informed regarding the process of patch testing and signed consent forms.

Results

Two hundred and fifteen patients (male 48, female 167) were recruited for patch testing. The median age was 45 years old. Fifty-nine patients (27.4%) had positive patch test reaction to at least 1 medicament and 13 of these patients (22%) had a relevant history. Nine patients showed co-sensitization to 2 allergens of medicament series and 11 patients showed positive results to more than 2 allergens. The 5 most common positive medicament allergens were framycetin 23/215 (10.7%), miconazole 22/215 (10.2%), econazole 17/215 (7.9%), caine mixes 11/215 (5.1%) and neomycin 6/215 (2.8%) (figure 1).

Data collection

Demographic data including age, sex, occupation and history of atopic eczema, duration of symptoms, affected area of the rash, suspected allergens by history from patients, history of previous treatment and medications were recorded. The characterization was performed according to the MOAHLE index (including Male, Occupation, Atopic dermatitis, Hand dermatitis, Leg dermatitis, Face dermatitis, Aged 40 years and above) and other suspected contributing factors.

Statistical analysis

Statistical analysis was performed by SPSS (version 17.0.2, 2009; SPSS Inc., Chicago, IL, USA). The Chi-square test was used to test for any significant difference between rate of medicament patch test positive and the patch test negative group, $p \leq 0.05$ was considered statistically significant.
Females were predominant amongst the medicament allergy group (79.7%), the mean age was 47 years, median onset of the rashes was 9 months and the most common location was the face (37.3%). The demographic data was shown in Table 1, however no statistical significance was found between the positive and negative medicaments groups. All 215 patients also had patch testing with the standard series, and 126 (58.6%) showed at least 1 positive standard allergen. Thirty-one patients (14.4%) had 2 positive allergens. Thirty-nine patients (18.1%) had more than 2 positive reactions and also showed a statistically significant higher rate of medicament sensitization ($p = 0.016$). The rate of positive patch test reaction to standard allergens, upon comparison between the positive and negative medicament groups, was shown in Figure 2. The most common positive standard allergens in medicament positive group were nickel (4.2%) followed by fragrance mix I (4.1%) whilst the medicament negative group found positive reaction to nickel (14%), MCI/MI 11.5% and PPD 8%. Moreover, patients with positive reactions to allergens in the fragrance groups (fragrance mix I, fragrance mix II, and Balsam of Peru) were significantly found to be in concurrent with positive medicament patch test ($p = 0.008$). Co-sensitization was found in more than one third of the medicament patch test positive patients.

Upon comparison between the medicament positive and negative group according to the MOAHLFA index (Table 2). Statistical significances were seen between Framycetin and facial dermatitis ($p = 0.031$), Econazole and older age ($p = 0.009$), together with caine mixed and longer duration of rashes ($p = 0.005$).

Other contributing factors showing a statistically significant association with positive medicament patch tests were having history of suspected allergens in personal care products and topical drugs ($p = 0.038$ and $p = 0.002$, respectively), history of any systemic drug allergy ($p = 0.023$), history of topical treatment ($p = 0.011$) and history of using combined topical corticosteroids and anti-fungal drugs ($p = 0.010$) (Table 3).

Chronological studies of medicament sensitization were shown in Table 4.

Table 1. Demographic data of all patients positive and negative to medicament series.

| Demographic data          | Patients (N = 215) | Patients with Positive Medicament series (N = 59) | Patients with Negative Medicament series (N = 156) | P-value * |
|---------------------------|-------------------|-----------------------------------------------|-------------------------------------------------|-----------|
| Sex                       |                   |                                               |                                                 |           |
| Male                      | 48 (22.3%)        | 12 (20.3%)                                    | 36 (23%)                                        | 0.717     |
| Female                    | 167 (77.6%)       | 47 (79.6%)                                    | 120 (76.9%)                                     | 0.717     |
| Mean age (years)          | 45                | 47                                            | 44                                              | 0.298     |
| Median duration of the rash (month) | 8 (2-24)     | 9 (2-36)                                      | 7.5(2-24)                                       | 0.275     |
| Area of rash              |                   |                                               |                                                 |           |
| Scalp                     | 8 (3.7%)          | 1 (1.7%)                                      | 7 (4.5%)                                        | 0.451     |
| Face                      | 68 (31.6%)        | 22 (37.3%)                                    | 46 (29.5%)                                      | 0.324     |
| Neck                      | 5 (2.3%)          | 3 (5.1%)                                      | 2 (1.3%)                                        | 0.128     |
| Trunk                     | 22 (10.2%)        | 6 (10.2%)                                     | 16 (10.3%)                                      | 1.000     |
| Upper extremities         | 6 (2.8%)          | 1 (1.7%)                                      | 5 (3.2%)                                        | 1.000     |
| Lower extremities         | 17 (7.9%)         | 6 (10.2%)                                     | 11 (70.5%)                                      | 0.571     |
| Hands                     | 37 (17.2%)        | 8 (13.6%)                                     | 29 (18.5%)                                      | 0.426     |
| Feet                      | 8 (3.7%)          | 3 (5.1%)                                      | 5 (3.2%)                                        | 0.687     |
| All over                  | 44 (20.5%)        | 10 (16.9%)                                    | 34 (21.8%)                                      | 0.570     |

Data are presented as n (%); *p < 0.05
Table 2. Comparison between the positive and negative medicament patch test according to the MOAHLFA index together with selected drug allergen.

|                          | Positive medicament patch test (n = 59) | Negative medicament patch test (n = 156) | p-value* |
|--------------------------|----------------------------------------|----------------------------------------|----------|
| Male                     | 12 (20.3%)                             | 36 (23.1%)                             | 0.667    |
| Occupational dermatosis  | 3 (5.1%)                               | 5 (3.2%)                               | 0.687    |
| Atopic dermatitis        | 3 (5.1%)                               | 7 (4.5%)                               | 1.000    |
| Hand eczema              | 8 (13.6%)                              | 29 (18.5%)                             | 0.426    |
| Leg dermatitis           | 6 (10.2%)                              | 11 (7.1%)                              | 0.571    |
| Face dermatitis          | 22 (37.3%)                             | 45 (28.8%)                             | 0.251    |
| Age > 40 years           | 39 (66.1%)                             | 81 (51.9%)                             | 0.067    |
| Duration (mo.) of the rash (median[IQR]) | 9 (2, 36)   | 7.5 (2, 24)                           | 0.206    |

Data are presented as n (%); *p < 0.05

Figure 2. Rate of positive patch test reaction to standard allergens.
### Table 3. Contributing factors in association with positive medicament patch test.

| Positive medicament Series (n = 59) | Negative medicament Series (n = 156) | p-value* |
|-------------------------------------|--------------------------------------|----------|
| History of systemic drug allergy    |                                      |          |
| Yes                                 | 13 (22%)                             | 13 (8.3%)| 0.023*    |
| No                                  | 46 (77.9%)                           | 143 (91.7%)|          |
| Name of systemic drug allergy       |                                      |          |
| Penicillin                          | 4 (6.67%)                            | 6 (3.87%)| 0.467     |
| Sulfa                               | 4 (6.67%)                            | 2 (1.29%)| 0.049     |
| History of previous treatment       |                                      |          |
| Yes                                 | 53 (89.8%)                           | 115 (73.7%)| 0.011*    |
| No                                  | 6 (10.2%)                            | 41 (26.3%)|          |
| Topical drug treatment              |                                      |          |
| None                                | 6 (10.2%)                            | 41 (26.3%)| 0.011*    |
| Steroid                             | 33 (55.9%)                           | 78 (50%)  | 0.437     |
| Antifungal                          | 8 (13.6%)                            | 11 (7.1%) | 0.134     |
| Antifungal with steroid             | 8 (13.6%)                            | 6 (3.8%)  | 0.010*    |
| Antibiotic                          | 2 (3.4%)                             | 2 (1.3%)  | 0.307     |
| History of contact dermatitis (allergen) |                      |          |
| Personal care products              | 6 (10.2%)                            | 5 (3.2%)  | 0.038*    |
| Topical drugs                       | 6 (10.2%)                            | 2 (1.3%)  | 0.002*    |
| Household chemicals                 | 6 (10.2%)                            | 17 (10.9%)| 0.878     |
| Other                               | 3 (5.1%)                             | 8 (5.1%)  | 0.990     |

Data are presented as n (%); *p < 0.05

### Table 4. Chronological studies of medicament sensitization.

| Study                  | Country | Population    | Common positive Medicament | Most common location | Common positive standard allergen* |
|------------------------|---------|---------------|----------------------------|----------------------|-----------------------------------|
| Goh et al.1 1989       | Singapore | Contact dermatitis | Total 22.5% Neomycin 7.8% Prolavin 7.1% | Upper and lower extremity | Colophony 3.3%               |
| Green et al.2 2007     | UK      | Contact dermatitis | Total 20.6% Neomycin 13.8% Gentamicin 6.6% *age > 70 years | Upper extremity | FM I 12.9% Myroxylon pereirae 8.1% Lanolin 4.5% *age > 70 years |
| Padua et al.2 2007     | Germany | Contact dermatitis | Framycetin 4.9% Gentamicin 3.3% | N/A                  | N/A                              |
| This study             | Thailand | Contact dermatitis | Framycetin 10.7% Miconazole 10.2% | Face                | Nickel 18.2% MCI/MI 15% FM I 9.6% |

*over all patient
Discussion

Goh et al. reported a high positive rate of medicament allergy at 22.5% in Singapore patients.1 Similar to Green et al. from the United Kingdom, who also identified topical medicament allergy at 20.6%.2 Our study found a slightly higher rate at 59/215 (27.4%) of patients with positive patch test reactions to at least 1 medicament. Once the relevance history was taken into consideration, the true rate of the relevance positive patch test was 13/59 (22.0%). The relevance history of the positive patch test was somewhat difficult to establish as the sensitization might have occurred several years ago. We also found the co-sensitization among different drugs in the same group with similar chemical structure which might contribute to the low rate of true relevance positive patch test. We would suggest a careful history taking of previous medicament exposure.

The demographic data of this study did not show significant differences between the medicament patch test positive and negative groups. Goh et al. and Green, et al. noted that contact sensitization to topical medicaments was common in advancing age due to the frequent use of topical medicaments and having longer exposure to various allergens.1,2 Many studies identified leg dermatitis and leg ulcer as influences on the propensity to develop a medicament allergy and the rate of sensitization increased with duration of the ulcer.3,8 Our study showed facial dermatitis as the most common clinical presentation, 3 times more than leg dermatitis in medicament positive group. In our hospital, leg ulcers and venous stasis of the legs were mainly referred to the surgery department. Only a few patients with leg dermatitis were referred to the dermatology division. Previous study found the association between atopic dermatitis and topical medicament allergy in children.9 Our study, despite the inclusion criteria of ≥ 18 years old, did not show any different between the medicament positive and negative groups in patients with atopic dermatitis as shown in the MOAHLFA index.

The antibiotics group was the most common positive medicament allergens.2,10 Framycetin was known as a common positive medicament patch test in association with leg dermatitis and leg ulcer for 5 decades.11,12 In our study, framycetin showed a rather high rate of positive medicament patch test at 10.7% in comparison to a previous study from Germany at 4.9%.7 Neomycin was our second most frequent positive medicament patch test at 2.8%. Framycetin and neomycin are aminoglycoside antibiotics that have closely related chemical structures. Cross-reaction among these 2 medicaments is quite frequent.13 Previous studies found the positive rate of 7.8% and 12.8% in Singapore and United Kingdom respectively.1,2 Another study from Canada reported a different most common positive patch test antibiotics i.e. bacitracin.10

Antifungal medicament allergy in our study is particularly high. Imidazoles were the most frequently prescribed topical antifungal drugs. Our study found miconazole was the most common positive patch test antifungal agent at 10.2%, followed by econazole at 7.9%. In our hospital econazole was an imidazole derivative used in combination with corticosteroid, Ecosone™. The combination drug was commonly prescribed to most patients with chronic paronychia. Upon correlation with our results, patients with a positive patch test to econazole were older than the negative group. However, the discrepancy might be explained by cross-sensitization within the same imidazole groups.14,15

Local anesthetics derived from caines are widely used not only in injectable preparations, but also in topical forms such as creams used for pruritus ani, hemorrhoids, sunburn relief and anesthetic eye or ear drops. Our study found the rate of contact sensitization to caine mixes was 5.1% which was the same as a previous report of 4.0%.16

Allergy to other agents such as cetostearyl alcohol may present as either medicament or cosmetic allergy or both. They are beyond the scope of this article.

The increasing number of positive patch tests to standard allergens also increased the number of topical medicament allergens among our patients. Regarding the co-sensitization, only fragrances showed a significantly increased rate of co-positive reaction to medicaments when compared with other standard allergens. Polysensitization, 3 or more contact allergies, is associated with increased sensitization to further allergens including weak sensitizers such as paraben mix, wool alcohols and neomycin.17,18 Many studies suggested the predisposing factors for polysensitization i.e. strong patch-test reactions, genetic factors, environment exposure, allergens in combination and concomitant skin diseases.17 Polysensitization could be one of the influent factors for medicament allergy. As a result, we suggested to discourage the overuse of topical medicament especially in polysensitized patients. Moreover, the positive medicament patients in our study significantly had a history of systemic drug allergy, which might support a genetic factor hypothesis.

We believe the discrepancy of our results from other areas of the world in terms of contact sensitizing medicament can be explained by the fact that most medication can be obtained without any prescription in Thailand and many South East Asian countries. Moreover, most people in Thailand prefer to try some drugs before getting a prescription, i.e. self-medication.

Our study showed other contributing factors associated with medicament allergy i.e. history of previous treatment, history of using topical combination drugs (corticosteroids, anti-fungal agents and/or antibiotics), and history of allergy to personal care products or topical drug. The need for primary exposure to allergens was an obvious explanation to associate medicament allergy with history of previous treatment and history of allergy to personal care products or topical drugs. Furthermore, polysensitization could also play a role. Interestingly, our data associated medicament allergy only with history of using topical combination drugs but not the single drug therapy. The result emphasized the need to encourage the general public to obtain proper prescriptions. Self-medication with combination drugs might lead to exposure of unnecessary drugs and potential sensitization.
This study was performed in a monocenter, which had a limited number of patients recruited into the study. The relevance of medicament sensitization was difficult to establish due to various unknown source of allergens e.g. herbal drugs and traditional medicine or the sensitization might have occurred many years ago.

Conclusion

The study showed a high rate of medicament sensitization among patients who required patch testing especially antibiotic and antifungal drugs. We found the incidence of positive medicament patch test result was not only associated with older age but also anatomical location of the skin lesion i.e. facial dermatitis according to the MOAHLFA index. Polysensitization and history of previous exposure, either as treatment or overusing of drugs, significantly associated with medicament positive patients. This study supports the inclusion of medicaments within the standard series of patch test.

Acknowledgement

We would like to thank Dr. Artit Nakakes M.D. and Dr. John McFadden BM, FRCP for their kind reading the manuscript.

Funding

No funding or sponsorship was received for this study or publication of this article

Conflicts of Interest

No conflict of interest

References

1. Goh CL. Contact sensitivity to topical medicaments. Int J Dermatol. 1989;28(1):25-8.
2. Green CM, Holden CR, Gawkrodger DJ. Contact allergy to topical medicaments becomes more common with advancing age: an age-stratified study. Contact Dermatitis. 2007;56(4):229-31.
3. Shih YH, Sun CC, Tseng YH, Chu CY. Contact dermatitis to topical medicaments: A retrospective study from a medical center in Taiwan. Dermatologica Sin. 2015;33(4): 181-6.
4. Goossens A, Medeiros S. Allergic contact dermatitis from topical medicaments. Expert Rev Dermatol. 2008;3(1):37–42.
5. Johansen JD, Aalto-Korte K, Agner T, Andersen KE, Bircher A, Bruze M, et al. European Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on best practice. Contact Dermatitis. 2015;73(1):195-221.
6. Uter W, Gefeller O, Geier J, Schnuch A. Changes of the patch test population (MOAHLFA index) in long-term participants of the Information Network of Departments of Dermatology, 1999-2006. Contact Dermatitis. 2008;59(1):56-7.
7. de Padua CA, Uter W, Schnuch A. Contact allergy to topical drugs: prevalence in a clinical setting and estimation of frequency at the population level. Pharmacoepidemiol Drug Saf. 2007;16(4):377-84.
8. Uter W, Geier J, Pfälzberg A, Effendy I. The spectrum of contact allergy in elderly patients with and without lower leg dermatitis. Dermatology. 2002; 204: 266–272.
9. Mailhol C, Lauwers-Cances V, Ranc_e F, Paul C, Giordano-Labadie F. Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: a study in 641 children. Allergy. 2009;64: 801-6
10. Spring S, Pratt M, Chaplin A. Contact dermatitis to topical medicaments: a retrospective chart review from the Ottawa Hospital Patch Test Clinic. Dermatitis. 2012; 23(5), 210-3.
11. Fräki JE, Peltonen L, Hoposu-Havu VK. Allergy to various components of topical preparations in stasis dermatitis and leg ulcer. Contact Dermatitis. 1979;5:97-100.
12. Rai R, Shenoy MM, ViswanathV, Sarma N, Majid I, Dogra S. Contact sensitivity in patients with venous leg ulcer: A multi-centric Indian study. Int Wound J. 2018;15(4),618–22
13. Rietschel RL, Fowler JF, Fisher AA. Fisher's contact dermatitis: PMPH-USA; 2008.
14. Carlsen BC, Andersen KE, Menne T, Johansen JD. Patients with multiple contact allergies: a review. Contact Dermatitis. 2008;58(1):1-8.
15. Schnuch A, Brach J, Lessmann H, Geier J, Uter W. A further characteristic of susceptibility to contact allergy: sensitization to a weak contact allergen is associated with polysensitization. Results of the IVDK. Contact Dermatitis. 2007;56(6):331-7.